摘要
目的 :观察奈达铂 (Nedaplatin,NDP)治疗晚期非小细胞肺癌 (NSCL C)的疗效及不良反应。方法 :将初治 NSCL C病人按数字随机法分成试验组和对照组 ,试验组 :NDP10 0 mg/ m2 ,静注 ,第 1天 ;长春地辛 (VDS) 3mg/ m2 ,静注 ,第 l、5天。对照组 :顺铂 80～ 10 0 m g/ m2 ,静注 (联合水化 ) ,平均分在连续 3d内使用 ;VDS3mg/ m2 ,静注 ,第 l、5天。两个方案均为每 3周为1个周期。结果 :入组的 36例病例均可评价疗效 ,试验组 16例 ,有 3例取得 PR,SD5例 ,PD8例 ,有效率 (RR)为 18.8% (3/18) ;对照组 2 0例 ,获 PR4例 ,SD8例 ,PD8例 ,RR为 2 0 % (4 / 2 0 )。两组均无 CR病例 ,两组的有效率相当 (P >0 .0 5 )。骨髓抑制是两个方案的主要不良反应 ,两组的贫血、白细胞减少发生率均较高 ,但差异无统计学意义。两组的血小板减少发生率均不足 2 0 %。除了对照组呕吐的发生率明显高于试验组外 (P <0 .0 5 ) ,两组的其他不良反应相近 (均 P >0 .0 5 )。结论 :NDP联合方案对晚期的 NSCL C有一定的疗效 ,病人耐受性好 ,不良反应主要为骨髓抑制 。
Objective:To observe the efficacy and the side effects of nedaplatin in treatment of advanced non small cell lung cancer (NSCLC).Methods:The chemonaive patients with NSCLC were randomized to two groups: the observed group was treated with nedaplatin(100 mg/m 2,iv,d1) plus vindesine (VDS 3 mg/m 2,iv,d1,5,every 3 weeks), and the control group was treated with cisplatin (DDP,80~100mg/m2,iv,d1,or 30mg/m 2,iv,d1~3) plus VDS(VDS3mg/m 2,iv,d1,5, every 3 weeks).Result:16 patients were in the observed group and 20 patients were in the control group, the response rates were 18.8% and 20%, respectively. The two group had similar incidence rate of anemia, neutropenia and thrombocytopenia But the incidence rate of vomiting was higher in the control group than that in the observed group(P<0 05).Conclusion:Nedaplatin combined with vindesine is an effective and well tolerable regimen in the treatment of advanced NSCLC. The main side effects of this regimen was bone marrow suppression.
出处
《广西医科大学学报》
CAS
2003年第4期493-495,共3页
Journal of Guangxi Medical University
关键词
奈达铂
顺铂
非小细胞肺癌
化学治疗
nadeplatin
cisplatin
non small cell lung cancer
chemotherapy
